In Vivo Distribution of Surface-modified PLGA Nanoparticles Following Intravaginal Delivery

Overview

Journal J Control Release

Specialty Pharmacology

Date 2011 Jul 19

PMID 21763739

Citations 46

Authors

Yen Cu

Carmen J Booth

W Mark Saltzman

Affiliations

Soon will be listed here.

Abstract

Intravaginal (ivag) delivery, which is a proven way to confer local protection against STDs contracted via the reproductive tract, is complicated by the mucus gel barrier, the hormone cycle, and the harsh mucosal environment that leads to low residence-time for administered agents. Polymer delivery vehicles may be useful in overcoming these barriers. In this study, we explored the fate of nanoparticles (NP) made from poly(lactide-co-glycolide) (PLGA) in the mouse reproductive tract after ivag delivery. The nanoparticles were modified to display avidin (Avid-NP) or 2 kDa PEG (PEG-NP) on their surface. Vaginal retention fractions for both muco-adhesive Avid-NP and stealthy PEG-NP were 5× higher than unmodified PLGA particles (NP). The amount of particles associated with mucus differed across formulations (Avid-NP>NP>PEG-NP). PEG-NP was found at higher concentration in the tissue than Avid-NP and NP up to 6h after delivery, and particles were found within epithelial cells, the underlying submucosal stromal and fibroblast cells of the vaginal tissue. Our results demonstrate that surface properties of nanoparticles can impact their fates following ivag delivery. Moreover, we show that the muco-evasive PEG-modified nanoparticles are the most effective among the delivery vehicles tested for this application.

Citing Articles

and assessment of an optimized QbD-guided myoinositol and metformin-loaded mucus-penetrating particle-based gel for the amelioration of PCOS.

Farooq U, Aamir Mirza M, Alshetaili A, Mohapatra S, Jain P, Hassan N Nanoscale Adv. 2024; 6(2):648-668.

PMID: 38235090 PMC: 10791119. DOI: 10.1039/d3na00943b.

Delivery and short-term maternal and fetal safety of vaginally administered PEG-PLGA nanoparticles.

Irvin-Choy N, Nelson K, Gleghorn J, Day E Drug Deliv Transl Res. 2023; 13(12):3003-3013.

PMID: 37365402 PMC: 10913101. DOI: 10.1007/s13346-023-01369-w.

In vitro and ex vivo models for evaluating vaginal drug delivery systems.

Shapiro R, DeLong K, Zulfiqar F, Carter D, Better M, Ensign L Adv Drug Deliv Rev. 2022; 191:114543.

PMID: 36208729 PMC: 9940824. DOI: 10.1016/j.addr.2022.114543.

Recent Advances in Polymer-Based Vaginal Drug Delivery Systems.

Osmalek T, Froelich A, Jadach B, Tatarek A, Gadzinski P, Falana A Pharmaceutics. 2021; 13(6).

PMID: 34203714 PMC: 8232205. DOI: 10.3390/pharmaceutics13060884.

Size-dependent biodistribution of thiol-organosilica nanoparticles and F4/80 protein expression in the genital tract of female mice after intravaginal administration.

Awaad A, Nakamura M Histochem Cell Biol. 2021; 155(6):683-698.

PMID: 33656583 DOI: 10.1007/s00418-021-01974-1.

References

Kanazawa T, Takashima Y, Hirayama S, Okada H . Effects of menstrual cycle on gene transfection through mouse vagina for DNA vaccine. Int J Pharm. 2008; 360(1-2):164-70. DOI: 10.1016/j.ijpharm.2008.04.038. View

Brandhonneur N, Loizel C, Chevanne F, Wakeley P, Jestin A, Le Potier M . Mucosal or systemic administration of rE2 glycoprotein antigen loaded PLGA microspheres. Int J Pharm. 2009; 373(1-2):16-23. DOI: 10.1016/j.ijpharm.2009.01.020. View

Kuo-Haller P, Cu Y, Blum J, Appleton J, Saltzman W . Vaccine delivery by polymeric vehicles in the mouse reproductive tract induces sustained local and systemic immunity. Mol Pharm. 2010; 7(5):1585-95. PMC: 3004023. DOI: 10.1021/mp100009e. View

Woolfson A, Malcolm R, Gallagher R . Drug delivery by the intravaginal route. Crit Rev Ther Drug Carrier Syst. 2000; 17(5):509-55. View

Yamamoto H, Kuno Y, Sugimoto S, Takeuchi H, Kawashima Y . Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J Control Release. 2005; 102(2):373-81. DOI: 10.1016/j.jconrel.2004.10.010. View

Iwasaki A . Mucosal dendritic cells. Annu Rev Immunol. 2007; 25:381-418. DOI: 10.1146/annurev.immunol.25.022106.141634. View

Dhaliwal S, Jain S, Singh H, Tiwary A . Mucoadhesive microspheres for gastroretentive delivery of acyclovir: in vitro and in vivo evaluation. AAPS J. 2008; 10(2):322-30. PMC: 2751389. DOI: 10.1208/s12248-008-9039-2. View

Mestecky J, Moldoveanu Z, Russell M . Immunologic uniqueness of the genital tract: challenge for vaccine development. Am J Reprod Immunol. 2005; 53(5):208-14. DOI: 10.1111/j.1600-0897.2005.00267.x. View

Takeuchi H, Matsui Y, Sugihara H, Yamamoto H, Kawashima Y . Effectiveness of submicron-sized, chitosan-coated liposomes in oral administration of peptide drugs. Int J Pharm. 2005; 303(1-2):160-70. DOI: 10.1016/j.ijpharm.2005.06.028. View

10.

Yin Y, Chen D, Qiao M, Wei X, Hu H . Lectin-conjugated PLGA nanoparticles loaded with thymopentin: ex vivo bioadhesion and in vivo biodistribution. J Control Release. 2007; 123(1):27-38. DOI: 10.1016/j.jconrel.2007.06.024. View

11.

Cu Y, Saltzman W . Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus. Mol Pharm. 2008; 6(1):173-81. PMC: 2637413. DOI: 10.1021/mp8001254. View

12.

Abdool Karim Q, Abdool Karim S, Frohlich J, Grobler A, Baxter C, Mansoor L . Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329(5996):1168-74. PMC: 3001187. DOI: 10.1126/science.1193748. View

13.

Sakaguchi M, Sakai T, Adachi Y, Kawashima T, Awata N . The biological fate of sodium prasterone sulfate after vaginal administration. I. Absorption and excretion in rats. J Pharmacobiodyn. 1992; 15(2):67-73. DOI: 10.1248/bpb1978.15.67. View

14.

Cone R . Barrier properties of mucus. Adv Drug Deliv Rev. 2009; 61(2):75-85. DOI: 10.1016/j.addr.2008.09.008. View

15.

Vila A, Gill H, McCallion O, Alonso M . Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density. J Control Release. 2004; 98(2):231-44. DOI: 10.1016/j.jconrel.2004.04.026. View

16.

Thomas C, Gupta V, Ahsan F . Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses. Int J Pharm. 2009; 379(1):41-50. DOI: 10.1016/j.ijpharm.2009.06.006. View

17.

Mundargi R, Babu V, Rangaswamy V, Patel P, Aminabhavi T . Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Control Release. 2007; 125(3):193-209. DOI: 10.1016/j.jconrel.2007.09.013. View

18.

Shen H, Ackerman A, Cody V, Giodini A, Hinson E, Cresswell P . Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology. 2006; 117(1):78-88. PMC: 1782199. DOI: 10.1111/j.1365-2567.2005.02268.x. View

19.

Chatterton B, Penglis S, Kovacs J, Presnell B, Hunt B . Retention and distribution of two 99mTc-DTPA labelled vaginal dosage forms. Int J Pharm. 2004; 271(1-2):137-43. DOI: 10.1016/j.ijpharm.2003.11.006. View

20.

Behrens I, Pena A, Alonso M, Kissel T . Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport. Pharm Res. 2002; 19(8):1185-93. DOI: 10.1023/a:1019854327540. View